Biological E to use Dynavax’s adjuvant in Corbevax

July 06, 2021 10:40 pm | Updated 10:40 pm IST - HYDERABAD

Biological E (BE) on Tuesday said it will use U.S. biopharmaceutical firm Dynavax Technologies Corporation’s CpG 1018 advanced adjuvant in its sub unit COVID-19 vaccine candidate Corbevax.

The firms have entered into a commercial supply agreement that extends through 2022. The agreement includes doses for delivery in 2021, which were manufactured under the previously announced funding agreement between the Coalition for Epidemic Preparedness Innovations (CEPI) and Dynavax, said Biological E, which expects to unveil Corbevax later this year subject to regulatory approvals.

Last month, while stating it had finalised arrangements with Biological E to reserve 30 crore doses of the vaccine, the Union Ministry of Health had said the vaccine was undergoing Phase-3 clinical trial after showing promising results in Phase 1 and 2.

A RBD protein sub-unit vaccine, it is likely to be available in the next few months. The vaccine doses will be manufactured and stockpiled by Biological-E from August-December 2021. For this purpose, an advance payment of ₹1,500 crore would be made to the company, the Ministry had said.

While Biological E MD Mahima Datla said Corbevax would play a critical role in eradicating the global pandemic, Dynavax CEO Ryan Spencer said the company was proud to extend collaboration with BE with a commercial supply agreement and deliver significant amounts of CpG 1018. The adjuvant was used in Heplisav-B, an adult hepatitis B vaccine approved by the USFDA and the European Commission.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.